Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells

Enhancing proteotoxic stress as an anticancer strategy

(2015) Steven Grant   Oncotarget

Bortezomib Targets the Caspase-Like Proteasome Activity in Cervical Cancer Cells, Triggering Apoptosis That Can be Enhanced by Nelfinavir

(2011) A. Bruning et al.   CURRENT CANCER DRUG TARGETS

Modulation of CCAAT/Enhancer Binding Protein Homologous Protein (CHOP)-dependent DR5 Expression by Nelfinavir Sensitizes Glioblastoma Multiforme Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)

(2011) Xiaobing Tian et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Noxa/Bcl-2 Protein Interactions Contribute to Bortezomib Resistance in Human Lymphoid Cells

(2011) Alyson J. Smith et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003)

(2011) Suresh S. Ramalingam et al.   Journal of Thoracic Oncology

Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress

(2011) Ira Tabas et al.   NATURE CELL BIOLOGY

Key role of ATF3 in p53-dependent DR5 induction upon DNA damage of human colon cancer cells

(2011) K Taketani et al.   ONCOGENE

Proteasome inhibitors in cancer therapy

(2011) Lisa J. Crawford et al.   Journal of Cell Communication and Signaling

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

(2010) Angela M. Davies et al.   Journal of Thoracic Oncology

Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors

(2010) Floriana Morgillo et al.   LUNG CANCER

Biological and Chemical Approaches to Diseases of Proteostasis Deficiency

(2009) Evan T. Powers et al.   Annual Review of Biochemistry

Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death

(2009) Peter M. Voorhees et al.   BRITISH JOURNAL OF HAEMATOLOGY

Inhibition of eIF2α Dephosphorylation Maximizes Bortezomib Efficiency and Eliminates Quiescent Multiple Myeloma Cells Surviving Proteasome Inhibitor Therapy

(2009) Denis M. Schewe et al.   CANCER RESEARCH

ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells

(2009) Q. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

CAAT/Enhancer Binding Protein Homologous Protein-Dependent Death Receptor 5 Induction Is a Major Component of SHetA2-Induced Apoptosis in Lung Cancer Cells

(2008) Y.-D. Lin et al.   CANCER RESEARCH

Role of the Aggresome Pathway in Cancer: Targeting Histone Deacetylase 6-Dependent Protein Degradation

(2008) A. Rodriguez-Gonzalez et al.   CANCER RESEARCH

Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors

(2008) Y.-C. Wang et al.   CANCER RESEARCH

Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

(2008) R. Z. Orlowski et al.   CLINICAL CANCER RESEARCH

Anti-HIV drugs for cancer therapeutics: back to the future?

(2008) Warren A Chow et al.   LANCET ONCOLOGY

Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis

(2008) M. Kraus et al.   MOLECULAR CANCER THERAPEUTICS